HOUSE_OVERSIGHT_024722.jpg
2.15 MB
Extraction Summary
0
People
8
Organizations
1
Locations
3
Events
1
Relationships
4
Quotes
Document Information
Type:
Investment report / industry analysis
File Size:
2.15 MB
Summary
This document is page 86 of a December 2017 Cannabis Investment Report by Ackrell Capital. It discusses the regulatory landscape involving the DEA and FDA, specifically highlighting GW Pharmaceuticals' NDA for Epidiolex and providing six predictions regarding the path to federal cannabis legalization in the US. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
Organizations (8)
Timeline (3 events)
October 2017
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
USA
Locations (1)
| Location | Context |
|---|---|
Relationships (1)
Ackrell Capital report discusses GW Pharmaceuticals' NDA submission.
Key Quotes (4)
"Many observers expect that Epidiolex will be the first cannabis-derived drug approved by the FDA."Source
HOUSE_OVERSIGHT_024722.jpg
Quote #1
"We predict six developments on the path to federal legalization"Source
HOUSE_OVERSIGHT_024722.jpg
Quote #2
"Cannabis parts and derivatives will be removed from the CSA schedules... and will be fully legal for medical and recreational purposes."Source
HOUSE_OVERSIGHT_024722.jpg
Quote #3
"Almost certainly, our predictions will prove inaccurate in some respects."Source
HOUSE_OVERSIGHT_024722.jpg
Quote #4
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document